Background Drug survival is a marker for treatment sustainability in chronic diseases such
as psoriasis. Objective The aim of these analyses was to assess survival of biologic …

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type
psoriasis: results from a phase 3 clinical trial (LOTUS). - Abstract - Europe PMC Sign in …

BACKGROUND: Ustekinumab has been evaluated in Caucasian patients with psoriasis, but
no studies have been conducted in Asian patients. OBJECTIVE: To assess the efficacy and …

Background Few data exist regarding the effectiveness of ustekinumab in inflammatory
bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to …

Serious infection is a concern for patients with psoriasis receiving biologic therapies. We
assessed the risk of serious infections for biologics used to treat psoriasis by comparison …

Introduction Our aim was to study drug survival and associated costs of biologic treatment in
a German real-world cohort of biologic-naïve psoriasis patients. Methods We utilized a …

Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably
affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal …

Background: The management of HIV-positive patients with psoriasis is controversial and
limited to individual cases or short series of patients. Objectives: To evaluate the safety and …

Background Comparing effectiveness of biologics in real-world settings will help inform
treatment decisions. Objectives We sought to compare therapeutic responses among …

Background: Drug survival in a real-life setting is critical to long-term use of biologics for
psoriasis. Objective: We describe our 12-year experience with biologics in psoriasis …